Shanghai OPM Biosciences Co., Ltd. (SHA:688293)

Market Cap	5.74B +22.0%
Revenue (ttm)	453.39M +50.5%
Net Income	66.26M +310.5%
EPS	0.30 +112.7%
Shares Out	139.27M
PE Ratio	139.69
Forward PE	63.40
Dividend	0.43 (0.96%)
Ex-Dividend Date	n/a

Volume	2,802,014
Open	44.68
Previous Close	44.96
Day's Range	40.50 - 44.82
52-Week Range	36.61 - 67.80
Beta	0.86
Analysts	Strong Buy
Price Target	53.41 (+29.6%)
Earnings Date	Aug 21, 2026

About Shanghai OPM Biosciences

Shanghai OPM Biosciences Co., Ltd. provides cell culture media and CDMO services in China and internationally. The company offers cell culture media and feed supplements, such as OPM's CHO-Platform, OPM-293 Platform, and VegaCHO media and feeds, as well as customized cell culture media development services. It also provides end-to-end biologics CDMO services, such as antibody discovery, stable cell line development, cell banking, upstream process development, downstream process development, formulation development, and quality control and produ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 367
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688293

Financial Performance

In 2025, Shanghai OPM Biosciences's revenue was 354.91 million, an increase of 19.40% compared to the previous year's 297.24 million. Earnings were 41.70 million, an increase of 98.07%.